Akumin Inc. (TSX: AKU.U) completed bought deal offering of 8,750,000 common shares at US $4.00 for gross proceeds of US $35,000,000. Clarus Securities Inc. led the offering.
Akumin (TSX: AKU.U) engaged Clarus Securities Inc. for a bought deal of 8,750,000 Common Shares at US $4.00 for gross proceeds of US $35,000,000
DiaMedica Therapeutics (TSX-V: DMA; OTCQB: DMCAF) closed second and final tranche of offering for gross proceeds of approximately US$2.5M. The company raised US $6.3M in two tranches.
Xenon Pharmaceuticals (NASDAQ: XENE) terminated collaborative development and license agreement with Teva Pharmaceuticals and closed share exchange transaction with Biotechnology Value Fund (BVF)
Profound Medical Corp. (TSX-V: PRN; OTCQX: PRFMF) closed previously announced bought for gross proceeds of $34.5M. Canaccord Genuity Corp. led the offering
Cognetivity Neurosciences Ltd. (CSE: CGN) commenced trading on the Canadian Securities Exchange (CSE) under the ticker symbol “CGN”.
HLS Therapeutics Inc. and Automodular Corporation completed RTO transaction
Immunovaccine Inc. (TSX: IMV; OTCQX: IMMVF) engaged Echelon Wealth Partners Inc. for a bought deal financing of 6,250,000 common shares at $2.00 per share for gross proceeds of $12.5 million
NOVA LEAP HEALTH CORP. (TSX-V: NLH) engaged Haywood Securities Inc. for a best efforts private placement of units at $0.25 for gross proceeds of a minimum of $1.25M and maximum of $2M